Patent ID: 6632815
Filing Date: 2003-10-14
Classification: C07C,C07D

Abstract:
A compound of formula (I):Aâ€”Qâ€”Dâ€”Gâ€”Jâ€”X wherein: A is phenyl, which is substituted with 0-2 R1 groups; each R1 is a member independently selected from the group consisting of: halo, â€”CN, â€”C(&boxH;O)â€”N(R2, R3), â€”NO2, â€”SO2N(R2, R3), â€”SO2R2, â€”(CH2)mNR2R3, â€”(CH2)mâ€”C(&boxH;NR3)â€”R2, â€”(CH2)mâ€”C(&boxH;NR2)â€”N(R2,R3), â€”(CH2)mâ€”N(R2)â€”C(&boxH;NR2)â€”N(R2,R3), â€”(CH2)mNR2â€”C3-6heterocyclics, C1-4alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C0-4alkylC3-8cycloalkyl, â€”CF3, â€”OR2, and a 5-6 membered heterocyclic system having from 1-4 hetero atoms each independently selected from the group consisting of N, O and S, wherein from 1-4 hydrogen atoms on the heterocyclic system may be independently replaced with a member selected from the group consisting of halo, C1-C4-alkyl, â€”CN, C1-4alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C0-4alkylC3-8cycloalkyl and â€”NO2; each of R2 and R3 is a member independently selected from the group consisting of: â€”H, â€”C1-6alkyl, â€”C1-6alkyloxy, â€”C2-6alkenyl, â€”C2-6alkynyl, â€”C3-8cycloalkyl, â€”C0-6alkylC3-8cycloalkyl and â€”C0-6alkyl-(carbocyclic aryl), wherein from 0-4 hydrogen atoms on the ring atoms of the carbocyclic aryl moiety may be independently replaced with a member selected from the group consisting of halo, â€”C1-4alkyl, â€”C2-6alkenyl, â€”C2-6alkynyl, â€”C3-8cycloalkyl, â€”C0-4alkylC3-8cycloalkyl, â€”S(&boxH;O)2â€”OH, â€”CN, â€”CF3 and â€”NO2; m is an integer of 0-2; Q is a direct link; D is phenyl, which is substituted with 0-2 R1a groups; each R1a is a member independently selected from the group consisting of: halo, â€”C1-6alkyl, â€”C1-6alkyloxy, â€”C2-6alkenyl, â€”C2-6alkynyl, â€”C3-8cycloalkyl, â€”C0-6alkylC3-8cycloalkyl, â€”S(&boxH;O)2â€”OH, â€”CN, â€”NO2, â€”(CH2)nâ€”N(â€”R2a, â€”R3a), â€”S(&boxH;O)2â€”N(â€”R2a, â€”R3a), â€”S(&boxH;O)2R2a, â€”CF3, â€”(CH2)nâ€”OR2a, â€”C(&boxH;O)â€”Oâ€”R2a, â€”C(&boxH;O)â€”N(â€”R2a, â€”R3a), â€”C(&boxH;NH)â€”N(â€”R2a, â€”R3a), â€”C(&boxH;NMe)â€”N(â€”R22, â€”R3a), 2-imidazolin-2-yl, 1-methyl-2-imidazolin-2-yl and a 5-6 membered aromatic heterocyclic ring having 1-4 heteroatoms each independently selected from the group consisting of N, O and S and â€”C0-6alkyl-(carbocyclic aryl), wherein from 0-4 hydrogen atoms on the ring atoms of the aromatic heterocyclic ring and the carbocyclic aryl moiety may be independently replaced with a member selected from the group consisting of halo, â€”C1-4alkyl, â€”C2-6alkenyl, â€”C2-6alkynyl, â€”C3-8cycloalkyl, â€”C0-4alkylC3-8cycloalkyl, â€”CN, â€”CF3 and â€”NO2; n is an integer of 0-2; each of R2a and R3a is a member independently selected from the group consisting of: â€”H, â€”C1-6alkyl, â€”C1-6alkyloxy, â€”C2-6alkenyl, â€”C2-6alkynyl, â€”C3-8cycloalkyl, â€”C0-6alkylC3-8cycloalkyl and â€”C0-6alkyl-(carbocyclic aryl), wherein from 0-4 hydrogen atoms on the ring atoms of the carbocyclic aryl moiety may be independently replaced with a member selected from the group consisting of halo, â€”C1-4alkyl, â€”C2-6alkenyl, â€”C2-6alkynyl, â€”C3-8cycloalkyl, â€”C0-4alkylC3-8cycloalkyl, â€”S(&boxH;O)2â€”OH, â€”CN, â€”CF3 and â€”NO2; E is â€”NHâ€”C(&boxH;O)â€”; G is a pyrazolyl, which is substituted with 0-2 R1b groups; each R1b is a member independently selected from the group consisting of: halo, â€”C1-6alkyl, â€”C2-6alkenyl, â€”C2-6alkynyl, â€”C3-8cycloalkyl, â€”C0-6alkylC3-8cycloalkyl, â€”C1-4alkyl-C(&boxH;O)â€”OH, â€”CN, â€”NO2, â€”S(&boxH;O)2â€”OH, â€”N(â€”R2b, â€”R3b), â€”C(&boxH;O)â€”N(â€”R2b, â€”R3b), â€”S(&boxH;O)2â€”N(â€”R2b, â€”R3b), â€”S(&boxH;O)2â€”R2b, â€”CF3, â€”Oâ€”R2b, â€”Oâ€”CH2â€”CH2â€”Oâ€”R2b, â€”Oâ€”CH2â€”C(&boxH;O)â€”Oâ€”R2b, â€”N(â€”R2b)â€”CH2â€”CH2â€”Oâ€”R2b, â€”N(â€”CH2â€”CH2â€”Oâ€”R2b)2, â€”N(â€”R2b)â€”C(&boxH;O)â€”R3b, â€”N(â€”R2b)â€”S(&boxH;O)2â€”R3b, and 5-6 membered heterocyclic ring having 1-4 hetero atoms each independently selected from the group consisting of N, O and S, substituted with 0-4 R1bâ€² groups; each of R2b and R3b is a member independently selected from the group consisting of: â€”H, â€”C1-6alkyl, â€”C1-6alkyloxy, â€”C2-6alkenyl, â€”C2-6alkynyl, â€”C3-8cycloalkyl, â€”C0-6alkylC3-8cycloalkyl and â€”C0-6alkyl-(carbocyclic aryl), wherein from 0-4 hydrogen atoms on the ring atoms of the carbocyclic aryl moiety may be independently replaced with a member selected from the group consisting of halo, â€”C1-4alkyl, â€”C2-6alkenyl, â€”C2-6alkynyl, â€”C3-8cycloalkyl, â€”C0-4alkylC3-8cycloalkyl, â€”S(&boxH;O)2â€”Oâˆ’, â€”CN, â€”CF3 and â€”NO2; each R1bâ€² is a member independently selected from the group consisting of: halo, â€”C1-6alkyl, â€”C2-6alkenyl, â€”C2-6alkynyl, â€”C3-8cycloalkyl, â€”C0-6alkylC3-8cycloalkyl, â€”C1-4alkyl-C(&boxH;O)â€”OH, â€”CN, â€”NO2, â€”S (&boxH;O)2â€”OH, â€”N(â€”R2bâ€², â€”R3bâ€²), â€”C(&boxH;O)â€”N(â€”R2bâ€², â€”R3bâ€²), â€”S(&boxH;O)2â€”N(R2bâ€², â€”R3bâ€²) â€”S(&boxH;O)2â€”R2bâ€²,â€”CF3, â€”Oâ€”R2bâ€², â€”Oâ€”CH2â€”CH2â€”Oâ€”R2bâ€², â€”Oâ€”CH2â€”C(&boxH;O)â€”Oâ€”R2bâ€², â€”N(â€”R2bâ€²)â€”CH2â€”CH2â€”Oâ€”R2bâ€², â€”N(â€”CH2â€”CH2â€”Oâ€”R2bâ€²)2, â€”N(â€”R2bâ€²)â€”C(&boxH;O)â€”R3bâ€² and â€”N(â€”R2bâ€²)â€”S(&boxH;O)2â€”R3bâ€²; each of R2bâ€² and R3bâ€² is a member independently selected from the group consisting of: â€”H, â€”C1-6alkyl, â€”C1-6alkoxy, â€”C2-6alkenyl, â€”C2-6alkynyl, â€”C3-8cycloalkyl, â€”C0-6alkylC3-8cycloalkyl and â€”C0-6alkyl-(carbocyclic aryl), wherein from 0-4 hydrogen atoms on the ring atoms of the carbocyclic aryl moiety may be independently replaced with a member selected from the group consisting of halo, â€”C1-4alkyl, â€”C2-6alkenyl, â€”C2-6alkynyl, â€”C3-8cycloakyl, â€”C0-4alkylC3-8cycloalkyl, â€”S(&boxH;O)2â€”OH, â€”CN, â€”CF3 and â€”NO2; J is a direct link X is a naphthyl, which is substituted with 0-3 R1c groups; each R1c is a member independently selected from the group consisting of: halo, â€”CF3, â€”C1-6alkyl, â€”C2-6alkenyl, â€”C2-6alkynyl, â€”C0-6alkylC3-8cycloalkyl, â€”C1-4alkyl-C(&boxH;O)â€”OH, â€”CF3, â€”CN, â€”NO2, â€”N(â€”R2c, â€”R3c), â€”C(&boxH;O)â€”N(â€”R2c, â€”R3c), â€”C(&boxH;NH)â€”N(â€”R2c, â€”R3c), â€”C(&boxH;NMe)â€”N(â€”R2c, â€”R3c), â€”S(&boxH;O)2â€”N(â€”R2c,â€”R3c), â€”S(&boxH;O)2â€”R2c, â€”S(&boxH;O)2â€”OH, â€”Oâ€”R2c, â€”O(â€”CH2)zâ€”Oâ€”R2c, â€”O(â€”CH2) zâ€”C(&boxH;O)â€”Oâ€”R2c, â€”O(â€”CH2)zâ€”Oâ€”R2c, â€”N[(â€”CH2)zâ€”Oâ€”R2c]2, â€”(CH2)zâ€”N(â€”R2c)â€”C(&boxH;O)â€”R3c, â€”(CH2)zâ€”N(â€”R2c)â€”S(&boxH;O)2â€”R3c, and a 5-6 membered heterocyclic ring having 1-4 heteroatoms each independently selected from the group consisting of N, O and S; z is an integer of 0-4; each of R2c and R3c is a member independently selected from the group consisting of: â€”H, â€”C1-6alkyl, â€”C1-6alkyloxy, â€”C2-6alkenyl, â€”C2-6alkynyl, â€”C3-8cycloalkyl, â€”C0-6alkylC3-8cycloalkyl and â€”C0-6alkyl-(carbocyclic aryl), wherein from 0-4 hydrogen atoms on the ring atoms of the carbocyclic aryl moiety may be independently replaced with a member selected from the group consisting of halo, â€”C1-4alkyl, â€”C2-6alkenyl, â€”C2-6alkynyl, â€”C3-8cycloalkyl, â€”C0-4alkylC3-8cycloalkyl, â€”S(&boxH;O)2â€”OH, â€”CN, â€”CF3 and â€”NO2; or all pharmaceutically acceptable diastereomers, enantiomers or mixtures thereof, salts, hydrates or solvates thereof.